Review
Oncology
Mathieu Larroquette, Charlotte Domblides, Matthieu Lasserre, Amandine Quivy, Baptiste Sionneau, Pauline Bertolaso, Marine Gross-Goupil, Alain Ravaud, Amaury Daste
Summary: The combination of immune checkpoint inhibitors and chemotherapy has shown improved overall survival and better objective response rates in certain solid tumors, especially in non-small cell lung cancer and PD1/PD-L1 enriched tumors, indicating potential synergistic effects of this treatment combination. However, the optimal approach between sequential and concomitant administration of chemoimmunotherapy remains controversial in cancer treatment strategies.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Immunology
Michela Roberto, Catia Carconi, Micaela Cerreti, Francesca Matilde Schipilliti, Andrea Botticelli, Federica Mazzuca, Paolo Marchetti
Summary: Recent focus on the human microbiota and its interaction with the human body has been facilitated by advancements in genome sequencing and bioinformatics. Diet plays a key role in shaping the microbiota's structure and function, which in turn can enhance the efficacy of immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Rom Leidner, Kevin Conlon, Douglas G. Mcneel, Andrea Wang-Gillam, Sumati Gupta, Robert Wesolowski, Monica Chaudhari, Nadia Hassounah, Jong Bong Lee, Lang Ho Lee, Jessica A. O'Keeffe, Nancy Lewis, George N. Pavlakis, John A. Thompson
Summary: This study investigated the efficacy and safety of NIZ985 as monotherapy and in combination with spartalizumab in the treatment of advanced solid tumors. The results showed that NIZ985 demonstrated antitumor activity and was well tolerated in patients with advanced solid tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Olivier J. van Not, Melissa M. de Meza, Alfons J. M. van den Eertwegh, John B. Haanen, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Jesper van Breeschoten, Jan-Willem B. de Groot, Geke A. P. Hospers, Rawa K. Ismail, Ellen Kapiteijn, Djura Piersma, Roos S. van Rijn, Marion A. M. Stevense-den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Han J. Bonenkamp, Marye J. Boers-Sonderen, Willeke A. M. Blokx, Michel W. J. M. Wouters, Karijn P. M. Suijkerbuijk
Summary: This study reveals the lower effectiveness of immune checkpoint inhibitors in patients with acral melanoma compared to cutaneous melanoma, with lower response rates, progression-free survival, and overall survival.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Immunology
Deqiang Wang, Xiaofeng Chen, Yian Du, Xiaoqin Li, Leqian Ying, Yi Lu, Bo Shen, Xuan Gao, Xin Yi, Xuefeng Xia, Xinbing Sui, Yongqian Shu
Summary: HER2 mutations may improve the tumor microenvironment to promote immunotherapy. A prospective basket trial is needed to further investigate the impacts of HER2 mutations on immunotherapy outcomes in solid tumors.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Konstantinos Tsiakos, Niki Gavrielatou, Ioannis A. Vathiotis, Loukas Chatzis, Stamatios Chatzis, Garyfallia Poulakou, Elias Kotteas, Nikolaos K. Syrigos
Summary: The immune system plays a crucial role in regulating immune responses, and immune checkpoint molecules are involved in both tumor and viral immune evasion. Studying the impact of immune checkpoint blockade on viral infections is important, and it could provide insight into the potential role of immunotherapy in treating viral infections.
Article
Immunology
Ying Wang, Mengxue Yang, Mingyang Tao, Peipei Liu, Cheng Kong, Hao Li, Yingmei Chen, Xudong Yin, Xuebing Yan
Summary: The use of corticosteroids for cancer-related indications in lung cancer patients receiving ICI treatment is associated with poorer prognosis, as demonstrated by meta-analysis and retrospective analysis. Subgroup analysis focusing on non-small cell lung cancer (NSCLC) showed similar results, highlighting the importance of careful selection of corticosteroid-treated patients for ICI therapy in personalized clinical management.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Oncology
Nuttapong Ngamphaiboon, Suthinee Ithimakin, Teerada Siripoon, Nattaya Sintawichai, Virote Sriuranpong
Summary: In Thai cancer patients treated with immune-checkpoint inhibitors (ICIs), immune-related adverse events (irAEs) were commonly observed, mainly low-grade and manageable. Re-occurrence of irAEs after re-challenging with ICIs was not uncommon. Patients with irAEs may have significantly longer overall survival (OS) compared to those without irAEs.
Article
Immunology
Xuebing Yan, Peipei Liu, Donglin Li, Ru Hu, Mingyang Tao, Siyuan Zhu, Wenjuan Wu, Mengxue Yang, Xiao Qu
Summary: Beta-blocker use may be associated with improved anti-cancer efficacy of immune checkpoint inhibitors (ICIs) in solid cancer patients, but its impact on overall prognosis remains uncertain.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Oncology
Laura Haik, Aurore Gonthier, Amandine Quivy, Marine Gross-goupil, Remi Veillon, Eric Frison, Alain Ravaud, Charlotte Domblides, Amaury Daste
Summary: Research shows that there is no significant difference in clinical outcomes and safety between patients with low muscle mass and those with non-low muscle mass treated with ICIs.
Article
Oncology
Anne Zaremba, Peter Mohr, Ralf Gutzmer, Friedegund Meier, Claudia Pfoehler, Michael Weichenthal, Patrick Terheyden, Andrea Forschner, Ulrike Leiter, Jens Ulrich, Jochen Utikal, Julia Welzel, Martin Kaatz, Christoffer Gebhardt, Rudolf Herbst, Anca Sindrilaru, Edgar Dippel, Michael Sachse, Frank Meiss, Lucie Heinzerling, Sebastian Haferkamp, Carsten Weishaupt, Harald Loeffler, Sophia Kreft, Klaus Griewank, Elisabeth Livingstone, Dirk Schadendorf, Selma Ugurel, Lisa Zimmer
Summary: This study analyzed the impact of NRAS gene mutations on melanoma patients treated with immune checkpoint inhibitors. The results showed that NRAS mutations were not significantly correlated with patients' survival and treatment response, and had no correlation with the expression of the T-cell immune checkpoint molecule PD-L1.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Mathilde Beaufils, Vincent Amodru, Manuel Tejeda, Jean Marie Boher, Christophe Zemmour, Brice Chanez, Anne Sophie Chretien, Laurent Gorvel, Gwenaelle Gravis, Damien Bruyat, Roxane Mari, Anne Madroszyk, Thomas Cuny, Anthony Goncalves, Aaron E. Lisberg, Daniel Olive, Louis Tassy, Frederic Castinetti, Philippe Rochigneux
Summary: Data mining analysis showed that immune checkpoint inhibitor (ICI)-induced dysthyroidism (DT) was associated with improved overall survival (OS), and patients with both DT and other immune-related adverse events had even longer OS.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Pharmacology & Pharmacy
Giandomenico Roviello, Luigi Francesco Iannone, Melissa Bersanelli, Enrico Mini, Martina Catalano
Summary: Immunotherapy has revolutionized cancer treatment, but reliable biomarkers for predicting treatment response are still unknown. Recent studies suggest that the gut microbiota may play a role in modulating the efficacy and toxicity of immunotherapy drugs.
PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Medicine, Research & Experimental
Hajar Alemohammad, Basira Najafzadeh, Zahra Asadzadeh, Amir Baghbanzadeh, Farid Ghorbaninezhad, Arezoo Najafzadeh, Hossein Safarpour, Renato Bernardini, Oronzo Brunetti, Margherita Sonnessa, Rossella Fasano, Nicola Silvestris, Behzad Baradaran
Summary: The growth and development of cancer are directly correlated to the suppression of the immune system, with immune checkpoints playing a key role in inhibiting anti-tumor immune responses. Up-regulation of inhibitory immune checkpoints on immune cells during tumor progression suppresses anti-tumor immune responses and promotes immune escape. Targeting inhibitory immune checkpoints through antibodies or miRNAs is a promising therapeutic strategy, and immune checkpoint inhibitors have shown favorable results in enhancing immune cell-induced antitumor responses.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Pharmacology & Pharmacy
Yatong Zhang, Yumei Tian, Li Zheng, Xuelin Sun, Zinan Zhao, Yujing Zheng, Jinhui Tian
Summary: The current review summarized real-world evidence on the efficacy and toxicity of consolidation durvalumab for stage III unresectable non-small cell lung cancer (NSCLC) after curative chemoradiotherapy. A total of 23 studies with 4,400 patients were included, showing that the 1-year overall survival (OS) and progression-free survival rates (PFS) of durvalumab were 85% and 60% respectively. Adverse events such as pneumonitis, endocrine, cutaneous, musculoskeletal, and gastrointestinal events were also reported. The results indicate that durvalumab has consistent short-term efficacy and safety with the PACIFIC trial.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Medicine, General & Internal
Jose-Manuel Ramos-Rincon, Paula Sol Ventura, Jose-Manuel Casas-Rojo, Marc Maurl, Carlos Lumbreras Bermejo, Aitor Ortiz de Latlerro, Manuel Rublo-Rivas, Luis Merida-Rodrigo, Lucia Perez-Casado, Vicente Giner-Galvan, Maria Barrientos-Guerrero, Cristina Gallego-Lezaun, Almudena Hernandez Milian, Luis Manzano, Julio Cesar Blazquez-Encinar, Marta Nataya Solis-Marquinez, Marcos Guzman Garcia, Julia Lobo-Garcia, Victoria Achaval-Rodriguez Valente, Celia Roig-Marti, Marta Leon-Tellez, Pablo Telleria-Gomez, Maria Jesus Gonzalez-Juarez, Ricardo Gomez-Huelgas, Alejandro Lopez-Escobar
Summary: This study aimed to validate the RIM Score-COVID in the SEMI-COVID-19 Registry and found that it showed good predictive ability for in-hospital COVID-19 mortality. The RIM Score-COVID is a simple and easy-to-use nomogram that uses clinical and analytical parameters to predict the risk of severe disease and death. The validation was done using data from consecutive patients hospitalized with confirmed COVID-19 in Spain.
INTERNAL AND EMERGENCY MEDICINE
(2023)
Letter
Gastroenterology & Hepatology
Cristina Martinez Cuevas, Miryam Moreta Rodriguez, Jose Pablo Miramontes-Gonzalez, Teresa Guerra Garijo
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS
(2023)
Article
Medicine, General & Internal
Carlos Gutierrez-Cerrajero, Eli Sprecher, Amy S. Paller, Masashi Akiyama, Juliette Mazereeuw-Hautier, Angela Hernandez-Martin, Rogelio Gonzalez-Sarmiento
Summary: This article summarizes the epidemiology, mechanisms, diagnosis, and treatment of ichthyosis, a group of dermatological disorders characterized by scaly, erythematous skin and epidermal barrier function disruptions. It also discusses the impact on patient quality of life and open research questions. Ichthyosis severely affects patient quality of life and currently available treatment options only provide symptomatic relief.
NATURE REVIEWS DISEASE PRIMERS
(2023)
Review
Oncology
Maria Ovejero-Sanchez, Rogelio Gonzalez-Sarmiento, Ana Belen Herrero
Summary: This article reviews the alterations in DNA damage response (DDR) pathways in ovarian cancer (OC), and the therapeutic potential of targeting the DDR for the treatment of OC. Failures in DDR have been associated with the development, progression, and chemoresistance of OC. Defects in DNA repair pathways, such as DNA double-strand break repair by homologous recombination and ARID1A mutations, have been found in different OC subtypes. Preclinical and clinical studies have shown promise in targeting the DDR to fight OC.
Review
Medicine, General & Internal
Carmen Suarez Fernandez, Pedro Armario, Jose Maria Cepeda, Maria Dolores Carmona Lopez, Jose Pablo Gonzalez Miramontes, Ismael Said-Criado
Summary: COVID-19 has negatively impacted the healthcare of cardiovascular disease patients and those at high risk. Access restrictions have led to poorer control and increased risk. Improving care during health emergencies is mandatory, including promoting telemedicine, patient empowerment, and better primary care coordination. Simplification and optimization of treatment, such as using cardiovascular polypills, have shown improved adherence and risk reduction. The document provides specific recommendations for improving care during health emergencies.
CURRENT MEDICAL RESEARCH AND OPINION
(2023)
Article
Biochemistry & Molecular Biology
Abel Martel-Martel, Luis A. Corchete, Marc Marti, Rosario Vidal-Tocino, Elena Hurtado, Edurne alvaro, Fernando Jimenez, Marta Jimenez-Toscano, Francesc Balaguer, Gonzalo Sanz, Irene Lopez, Sergio Hernandez-Villafranca, Araceli Ballestero, Alfredo Vivas, Sirio Melone, Carlos Pastor, Lorena Brandariz, Manuel A. Gomez-Marcos, Juan J. Cruz-Hernandez, Jose Perea, Rogelio Gonzalez-Sarmiento
Summary: The incidence of early-onset colorectal cancer (EOCRC; age younger than 50 years) has been increasing worldwide. This study explored the potential use of telomere length (TL) as a biomarker for EOCRC screening. TL was found to be significantly shorter in EOCRC patients compared to healthy individuals, suggesting a possible association between telomeric shortening and EOCRC susceptibility. Additionally, certain gene variants related to TL maintenance were found to be associated with the risk of developing EOCRC. Germline TL measurement and analysis of telomere maintenance gene polymorphisms could potentially facilitate early identification of individuals at risk of EOCRC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Alvaro Tamayo Velasco, Maria F. Munoz Moreno, Carmen Perez Martinez, Javier Martin Guerra, Jose M. Prieto De Paula, Jose P. Miramontes-Gonzalez
Summary: This study aims to investigate the association between high cobalamin levels and the development of cancer within five years. The results show that high cobalamin levels are closely related to the risk of hematologic malignancies, but not to other types of cancer.
Article
Medicine, General & Internal
J. Carretero-Gomez, F. J. Carrasco-Sanchez, J. M. Fernandez-Rodriguez, P. Casado-Escribano, J. P. Miramontes-Gonzalez, J. M. Segui-Ripoll, J. Ena, J. C. Arevalo-Lorido, representacion grp trabajo Diabet
Summary: The aim of this study was to evaluate the effect of weekly subcutaneous semaglutide on biomarkers of metabolic-associated fatty liver disease (MAFLD), specifically the hepatic steatosis index (HSI) and the fibrosis-4 (FIB-4) index, in outpatients attending internal medicine departments for 24 weeks. Participants were analyzed from an ongoing, multicenter, prospective, pre-post, uncontrolled cohort registry consisting of patients with type 2 diabetes receiving weekly subcutaneous semaglutide. The results showed that weekly subcutaneous semaglutide had a beneficial effect on liver steatosis beyond glucose control, mainly through weight loss, decline in biomarkers, and improvements in insulin sensitivity.
REVISTA CLINICA ESPANOLA
(2023)
Article
Biochemistry & Molecular Biology
Maria Fernandez-Regueras, Cristina Carbonell, Daniel Salete-Granado, Juan-Luis Garcia, Marcos Gragera, Maria-Angeles Perez-Nieto, Francisco-Javier Moran-Plata, Andrea Mayado, Jorge-Luis Torres, Luis-Antonio Corchete, Ricardo Usategui-Martin, Elena Bueno-Martinez, Maura Rojas-Pirela, Guadalupe Sabio, Rogelio Gonzalez-Sarmiento, Alberto Orfao, Francisco-Javier Laso, Julia Almeida, Miguel Marcos
Summary: Excessive alcohol consumption impairs the immune system, induces oxidative stress, and activates peripheral blood monocytes, contributing to alcoholic liver disease (ALD). This study analyzes the M1/M2 phenotypes of monocytes in excessive alcohol drinkers (EADs) and reveals the pro-inflammatory profile of circulating monocytes in EADs as well as the immune exhaustion features in macrophage-derived monocytes.
Article
Pediatrics
Monica Cano-Rosas, Joaquin de Vicente-Jimenez, Jose Maria Diosdado-Cano, David Suarez-Quintanilla, Rogelio Gonzalez-Sarmiento, Daniel Curto, Adrian Curto
Summary: This article presents the clinical course of a 9-year-old girl with Bloch-Sulzberger syndrome and severe neurological deficit. Longitudinal multidisciplinary follow-up was conducted from birth to adulthood. Neurological involvement was assessed using EEG and neuroimaging tests, while cranio-maxillofacial involvement was evaluated using facial and cephalometric analyses. Oral rehabilitation included orthodontic treatment and dental reconstruction to improve occlusion and masticatory function.
Letter
Gastroenterology & Hepatology
Miryam Moreta Rodriguez, Felix Garcia Pajares, Carolina Almohalla Alvarez, Carmen Alonso Martin, Antonio Gonzalez Lopez, Jose Pablo Miramontes Gonzalez, Javier Miguel Martin Guerra, Begona Morejon Huerta
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS
(2023)
Article
Clinical Neurology
Ricardo Usategui-Martin, Paloma Jimenez-Arribas, Carmen Sakas-Gandullo, Rogelio Gonzalez-Sarmiento, Carlos A. Rodriguez-Arias
Summary: The purpose of this study was to investigate the association between intracranial aneurysm (IA) rupture and subarachnoid hemorrhage, and to evaluate the impact of eNOS rs1799983 polymorphism on the risk of developing IA. The results showed that allele G of the eNOS rs1799983 polymorphism increased the risk of developing IA.
ACTA NEUROCHIRURGICA
(2023)
Article
Endocrinology & Metabolism
Sofia Siffo, Mauricio Gomes Pio, Elena Bueno Martinez, Katherine Lachlan, Joanna Walker, Jacques Weill, Rogelio Gonzalez-Sarmiento, Carina M. M. Rivolta, Hector M. Targovnik
Summary: The purpose of this study was to identify and functionally characterize new variants in the TG gene in order to increase the understanding of the molecular mechanisms responsible for thyroid dyshormonogenesis. Through the study of four patients from two non-consanguineous families, two deleterious alleles of the TG gene were identified. Further analysis predicted a new potential disease-causing variant. These results confirm the pathophysiological importance of altered TG folding in thyroid hormonegenesis.
Article
Biochemistry & Molecular Biology
Alejandro Olivares-Hernandez, Edel del Barco Morillo, Jose Pablo Miramontes-Gonzalez, Luis Figuero-Perez, Luis Perez-Belmonte, Javier Martin-Vallejo, Teresa Martin-Gomez, Roberto Escala-Cornejo, Rosario Vidal-Tocino, Lorena Bellido Hernandez, Rogelio Gonzalez Sarmiento, Maria Dolores Ludena de la Cruz, Juan Jesus Cruz-Hernandez, Carmen Parra Perez
Summary: This study evaluated the p53 protein expression in NSCLC as a predictive biomarker for the response to ICIs using IHC. Results showed that patients with high expression of p53 by IHC had a better response to ICIs in terms of PFS and OS, especially in the PD-L1 negative adenocarcinoma subgroup.
FRONTIERS IN BIOSCIENCE-LANDMARK
(2022)
Meeting Abstract
Biochemistry & Molecular Biology
Cristina Robles Lazaro, Maria Ovejero-Sanchez, Nerea Gestoso-Uzal, Carlos Gutierrez-Cerrajero, Paloma Martin-Bejarano Soto, Pamela Vazquez-Cardenas, Ana Belen Her-Rero, Rogelio Gonzalez-Sarmiento
EUROPEAN JOURNAL OF HUMAN GENETICS
(2022)